glp-1 agonists weight loss drugs market Report 2025-2033, By Product, Molecule, and Geo Costly GLP-1 Drugs are Rarely

This allows for the evaluation of the overall competition within the market

Never assume

doi: 10.1185/03007995.2010.549466 166 HamiltonAPattersonSPorterDGaultVAHolscherC

Here, additional data on the preventive health benefits of treating obesity will be key (e.g., SELECT trial for semaglutide) A company with asset(s) featuring compelling preclinical and clinical data demonstrating the above described profile could be positioned well to raise venture capital, even in todays challenging private financing market, and attract M&A activity from giants like Novo Nordisk and Eli Lilly

And when Novo Nordisk faced production issues, the decision to choose Eli Lilly's Mounjaro and Zepbound over Novo Nordisk's Wagovy became even easier

7 , e243604 (2024)